Aap Implantate : stops negotiations on the sale of Biomaterials GmbH shortly before completion - Strategy of transformation into a pure trauma company continues to be pursued consistently

aap Implantate AG (XETRA: AAQ.DE) today announced that negotiations on the sale of its subsidiary aap Biomaterials GmbH have been broken off at short notice. The company had reached a very advanced stage in discussions with a consortium of private equity bidders. A sale was not agreed, however, because the final transaction terms and conditions of aap Implantate AG could not be met.

"We were convinced until the end that we could close the transaction at attractive and mutual acceptable conditions but negotiations stalled at a critical point", says Bruke Seyoum Alemu, CEO of aap Implantate AG. "We were however - and still are - under no pressure to go ahead with the sale of our subsidiary. For us the focus was, from the outset, on concluding a transaction subject only to terms and conditions that are implementable in a reasonable period and reflect the right value of the company from a comparable transaction point of view. aap Biomaterials GmbH is a healthy and very profitable company which is especially characterized by strong cash flows. We will continue to grow our subsidiary and re-evaluate our options at a later date. As part of our strategy we continue to consistently pursue the objective of transforming aap Implantate AG into a leading European trauma company."

On the basis of the joint resolution by the Management Board and Supervisory Board to sell aap Biomaterials GmbH and the advanced state of the negotiations, aap Implantate AG drew up its consolidated financial statement as of December 31, 2014 on the assumption that the disposal of its subsidiary was imminent, requiring it to be stated as a discontinued operation. That led to extensive reporting requirements in the Notes and the Management Report as well as in various presentations of results in the consolidated financial statement. On the basis of all available information and in light of the breakdown of the negotiations a timely disposal of aap Biomaterials GmbH cannot be considered as likely. Consequently the subsidiary must be treated and presented as part of the aap Group. The extensive adjustments that this requires will lead to a delay in publication of the complete consolidated financial statement as of December 31, 2014. aap Implantate AG will nevertheless, as stated in the financial calendar, publish its consolidated and audited results of financial year 2014 (consolidated balance sheet, consolidated statement of comprehensive income, consolidated cash flow statement, consolidated statement of changes in equity and an overview of key financials) in the form of a press release.

Publication of aap Implantate AG's complete consolidated financial statement for 2014 is scheduled for April 30, 2014 at the latest.

About aap Implantate AG
aap is a global medical device company headquartered in Berlin, Germany that develops, manufactures and markets innovative biomaterials and implants that are used in orthopedic procedures. The Company's products, which include a full line of plating systems, cannulated screws and bone cement products, are primarily used in the orthopedic specialty areas of trauma and spine repair. The Company's products are sold through its direct sales force, distribution partners and license agreements with OEM partners. aap's stock is listed in the Prime Standard segment of the Frankfurt Stock Exchange. For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.

Forward-looking statement
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.

For inquiries please contact: aap Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke@aap.de